作者
G Orsi, M Di Marco, A Cavaliere, M Niger, S Bozzarelli, G Giordano, S Noventa, IG Rapposelli, I Garajova, G Tortora, MG Rodriquenz, A Bittoni, E Penzo, S De Lorenzo, U Peretti, C Paratore, I Bernardini, S Mosconi, A Spallanzani, M Macchini, E Tamburini, K Bencardino, E Giommoni, M Scartozzi, L Forti, MM Valente, AM Militello, S Cascinu, M Milella, M Reni
发表日期
2021/10/1
期刊
ESMO open
卷号
6
期号
5
页码范围
100238
出版商
Elsevier
简介
Background
Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different chemotherapy regimens in this setting.
Patients and methods
gBRCA1-2pv PDAC patients of any age and clinical tumor stage who completed a first course of chemotherapy were eligible. A descriptive analysis of chemotherapy toxicity, dose intensity, response, and survival outcomes was performed.
Results
A total of 85 gBRCA1-2pv PDAC patients treated in 21 Italian centers between December 2008 and March 2021were enrolled. Seventy-four patients were assessable for toxicity and dose intensity, 83 for outcome. Dose intensity was as follows: nab-paclitaxel 72%, gemcitabine 76% (AG); cisplatin 75%, nab-paclitaxel 73%, capecitabine 73%, and …
学术搜索中的文章
G Orsi, M Di Marco, A Cavaliere, M Niger, S Bozzarelli… - ESMO open, 2021